generations of glp 1 agonists Structures formulations of GLP-1 receptor [14, 15, 19–21, GLP-1R Agonists for Weight Loss

This week the Centers for Medicare & Medicaid Services (CMS) informed Medicare drug plans that they can cover Wegovy, another drug in this class, for its newly approved use of preventing heart attacks and strokes for people who are obese or overweight

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea

GLP-1 receptor agonists (GLP-1RAs) like semaglutide and tirzepatide are increasingly used in clinical practice, given their proven efficacy in managing obesity and type 2 diabetes (T2D) [1]

On the other hand, topical urea, not expected to influence outcomes, was used as a negative exposure control

However, clinical data relating to the potential of these drugs to improve bone health is only now beginning to emerge